Entrada Therapeutics Reports Positive Topline Data for DMD Treatment ENTR-601-45

Key highlights

• Primary safety and tolerability objectives met at initial 5 mg/kg dose
• Mean dystrophin production increased by 0.10% from baseline in treated participants
• Exon skipping demonstrated a 0.15% mean increase over baseline levels
• No study discontinuations, hypomagnesemia, or renal safety concerns were noted
• Topline data from the 10 mg/kg Cohort 2 is scheduled for release in H1 2027

Clinical Trial Progress and Outcomes

The ELEVATE-45-201 study is a Phase 1/2 trial evaluating ENTR-601-45 in ambulatory participants aged four to 20 with Duchenne muscular dystrophy amenable to exon 45 skipping. In Cohort 1, eight participants were randomized to receive 5 mg/kg of the therapeutic or a placebo across three doses. Beyond meeting safety markers, the study showed that plasma exposures were consistent with prior non-human primate data, providing a foundation for dose escalation. The most common adverse event reported was headache, with one participant experiencing resolved pyrexia and vomiting. All participants from the initial cohort have now transitioned into the Phase 2 open-label extension.

Strategic Platform Differentiators

• ENTR-601-45 utilizes the Endosomal Escape Vehicle platform to enhance intracellular delivery
• The current dosing schedule requires administration only once every six weeks
• Estimated annual burden of nine infusions compares to fifty-two for existing weekly treatments
• Independent Data Monitoring Committee has recommended escalation to higher doses in parallel studies
• Future cohorts will test doses of 10 mg/kg and up to 15 mg/kg to maximize dystrophin production

Impact on the Treatment Landscape

“Establishing a favorable safety profile at this initial dose in a three dose MAD study is the essential foundation for escalating to higher doses, and seeing any dystrophin produced in participants this young, with such low baseline levels, is an encouraging early signal.”

Financial and Market Context

Entrada Therapeutics maintains a specialized position within the biotechnology sector, focusing on Duchenne subpopulations with high unmet needs. As of mid-2026, the company reported a cash position of approximately $223 million, which is projected to fund operations through the third quarter of 2027. Despite the positive clinical update, the stock has experienced recent volatility, with a monthly decline of 28.53% and a Relative Strength Index (RSI) of 27.8, placing it in technically oversold territory. The company's annual revenue of $25.4 million is primarily driven by collaboration agreements as it continues to advance its clinical pipeline toward higher-dose readouts.

Management commentary

“For families currently managing a weekly infusion schedule, ENTR-601-45’s current dosing schedule translates to a potential therapy built around approximately nine administrations per year instead of more than fifty.”

Entrada Therapeutics, Inc. · financial snapshot

Share price	$4.86
Market cap	$189M
Revenue (annual)	$25M
1-month price change	-28.53%
Sector	HealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.